COVID-19 ワクチン vial 製造者 Stevanato 注目する，もくろむs $7 bln valuation in U.S. IPO
July 7 (Reuters) - Italy's Stevanato Group S.p.A., a 製造者 of glass vials for COVID-19 ワクチン and other healthcare 製品s, said on Wednesday it was 捜し出すing a valuation of over $7 billion in its U.S. 初期の public 申し込む／申し出ing (IPO).
設立するd by 億万長者 Sergio Stevanato, the company said in its とじ込み／提出するing that a total of 40 million 株 would be 申し込む／申し出d for sale 定価つきの between $21 and $24 each. The IPO would raise $960 million at the 最高の，を越す end of that 範囲.
About 30% of those 株 will be 申し込む／申し出d by the Stevenato family 持つ／拘留するing, an 存在するing 投資家. The proceeds from those 株 will not go to the company.
Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass 製造業者 that was the precursor to the 医療の 一括ing company.
The company started its international 拡大 in 2015 after the 購入（する） of a 最初の／主要な 一括ing company in Slovakia.
Stevanato, whose IPO 計画（する）s were 報告（する）／憶測d by Reuters in February, will 名簿（に載せる）／表（にあげる） on the New York 在庫／株 交流 under the symbol "STVN".
Morgan Stanley, BofA 安全s and Jefferies are the lead underwriters for the 申し込む／申し出ing.
(報告（する）／憶測ing by Niket Nishant in Bengaluru; Editing by Bernard Orr, Aditya Soni)
